Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00115375 · ClinicalTrials.gov registry record · Phase 2
Platelet Aggregation Inhibition in Children on Clopidogrel (PICOLO)
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
NCT00115375 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 92 participants.
The verdict
NCT00115375, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
Study Summary
PICOLO is a double blind placebo controlled phase II dose ranging, dose escalating study in patients of Blalock-Taussig age categories (neonates and infants/toddlers), to determine the dose providing inhibition of platelet aggregation similar to adults.
Interventions
- DRUG Clopidogrel (SR25990)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2004-01 |
| Est. Completion | 2006-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00115375
The ClinicalTrials.gov registry entry for NCT00115375 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Clopidogrel (SR25990) is the first listed.
NCT00115375 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00115375 about?
NCT00115375 is a clinical study titled "Platelet Aggregation Inhibition in Children on Clopidogrel (PICOLO)". PICOLO is a double blind placebo controlled phase II dose ranging, dose escalating study in patients of Blalock-Taussig age categories (neonates and infants/toddlers), to determine the dose providing inhibition of platelet aggregation similar to adults.
What is the current status of trial NCT00115375?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2004-01. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00115375?
The interventions under investigation include: Clopidogrel (SR25990) (DRUG).
Who is sponsoring clinical trial NCT00115375?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.